Description
BSE has received clarifications from Raymond Ltd, Sanstar Ltd, and Suven Life Sciences Ltd regarding significant price/volume movements. Reply is still awaited from ZR2 Bioenergy Ltd.
Summary
BSE’s Surveillance department observed significant price and volume movements in four companies and sought clarifications. Replies have been received from Raymond Ltd, Sanstar Ltd, and Suven Life Sciences Ltd, and are attached to the notice. ZR2 Bioenergy Ltd has not yet responded.
Key Points
- BSE observed abnormal price/volume movement in four scrips and initiated clarification requests
- Clarifications received from: Raymond Ltd (Scrip Code: 500330), Sanstar Ltd (Scrip Code: 544217), Suven Life Sciences Ltd (Scrip Code: 530239)
- Reply still awaited from ZR2 Bioenergy Ltd (Security Code: 506640)
- Notice issued by BSE Surveillance department on 19 May 2026 (Notice No. 20260519-15)
Regulatory Changes
No regulatory changes introduced. This is a surveillance-driven disclosure notice.
Compliance Requirements
- ZR2 Bioenergy Ltd is required to submit its clarification to BSE regarding the observed price/volume movement
- Trading members and investors are advised to review the attached replies from the three companies for relevant information
Important Dates
- Notice Date: 19 May 2026
- No specific deadline mentioned for ZR2 Bioenergy’s pending reply
Impact Assessment
The clarifications from Raymond Ltd, Sanstar Ltd, and Suven Life Sciences Ltd may contain material information relevant to recent price movements in these stocks. Investors and traders in these scrips should review the attached replies. The pending reply from ZR2 Bioenergy Ltd (506640) means uncertainty remains for that scrip until a clarification is provided.
Impact Justification
Routine surveillance clarification notice affecting four specific companies; replies received from three companies while one is still pending. Relevant to investors/traders in these specific scrips.